CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation

Mucosal Immunology, Published online: 17 March 2021; doi:10.1038/s41385-021-00388-5CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation

http://feeds.nature.com/~r/mi/rss/current/~3/9aeqPL1mTyw/s41385-021-00388-5

Source: Mucosal Immunology - March 17, 2021 Category: Allergy & Immunology Authors: Pedram Shafiei-Jahani Doumet Georges Helou Benjamin P. Hurrell Lauriane Galle-Treger Emily Howard Christine Quach Jacob D. Painter Marshall Fung Richard Lo Hooman Allayee Omid Akbari Source Type: research

More News: Allergy & Immunology